1. A local ophthalmic preparation consisting of an oil-in-water microemulsion containing: one or more fat-soluble active ingredients； an emulsifier consisting of d-α-tocopherylpolyethylene glycol 1000 succinate (TPGS)； an oil component consisting of medium chain triglycerides (MCT)； an ophthalmologically acceptable aqueous phase； in this case, the concentration of TPGS is from 0.1 to 5 wt%, and the mass ratio of MCT to TPGS is from 1: 2.8 to 1: 3.6, and the average size of the dispersed particles of the oil phase is not more than 100 nm, and I don’t exist no co-surfactants veschestva.2. The ophthalmic preparation according to claim 1, wherein said ratio is 1: 3.33, and said average particle size of the oil phase is not more than 20 nm. The ophthalmic preparation according to claim 2, in which the concentration of TPGS is from 1 to 2% by mass., And the concentration of MCT is from 0.25% to 1% by mass. An ophthalmic preparation according to any one of claims 1 to 3, containing from 0.002% to 5% by weight of a fat-soluble active ingredient. 5. The ophthalmic preparation according to claim 4, wherein said fat-soluble active ingredient is selected from the group consisting of: steroidal anti-inflammatory drugs, non-steroidal anti-inflammatory drugs, prostaglandin derivatives, calcineurin inhibitors or immunosuppressants, antioxidants, active ingredients of biotechnological origin. The ophthalmic preparation according to claim 5, wherein said ophthalmologically acceptable aqueous phase consists of an aqueous solution of glycerol. The ophthalmic preparation according to claim 5, further comprising1. Местный офтальмологический препарат, состоящий из микроэмульсии масло-в-воде, содержащей:один или несколько жирорастворимых активных ингредиентов；эмульгатор, состоящий из сукцината d-α-токоферилполиэтиленгликоля 1000 (TPGS)；масляный компонент, состоящий из среднецепных триглицеридов (МСТ)；офтальмологически приемлемую водную фазу；при этом концентрация TPGS составляет от 0,1 до 5
